Hormonal changes over time — and especially those around menopause — are often associated with disability worsening in multiple sclerosis (MS) patients, which suggests that sex-specific hormone therapies may be useful in MS treatment.
Burcu Zeydan, MD, assistant professor of neurology and radiology at Mayo Clinic, provided an overview of the current state of research into hormones and aging in her talk, “The Interactions of Sex, Hormones and Age in MS Prognosis,” during the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2022.
Biological sex is a critical factor affecting the development of MS, which is roughly three times more common in females than males. Females also develop the disease earlier than males, but males tend to have a faster rate of disability progression in the early stages of the disease.
Read more at: https://multiplesclerosisnewstoday.com/news-posts/2022/03/02/actrims2022-hormone-therapies-may-benefit-menopausal-ms-patients/